A Little Recognition, Please
Executive SummaryWall Street wasn't thrilled this August when T-Cell Sciences Inc. announced that it would acquire Virus Research Institute Inc. and its development-stage vaccines. But CEO Una Ryan, PhD, says the newly-merged company, Avant Immunotherapeutics Inc., is badly undervalued.
You may also be interested in...
CEO Vas Narasimhan is confident the Swiss major's gene therapy for spinal muscular atrophy will outperform present and future rivals – Biogen's Spinraza and Roche's risdiplam, respectively – as "we have a better profile simply because we are a one-time therapy."
A new coronavirus test template developed by the US Centers for Disease Control and Prevention is being refined by the agency so it can be shared with domestic and international partners to help identify more cases of the virus. In the meantime, state labs can use the posted assay for coronavirus on the CDC’s website for testing of residents within their jurisdiction and send results to the CDC.
The pharmaceutical industry will be watching carefully as the EU Court of Justice deliberates on whether to deny or widen the granting of supplementary protection certificates on new therapeutic indications of authorized medicines.